4-cyano CUMYL-BUTINACA (Item No. 20194) is an analytical reference standard that is structurally categorized as a synthetic cannabinoid. The physiological and toxicological properties of this compound are not known. 4-cyano CUMYL-BUTINACA is regulated as a Schedule I compound in the United States. This product is intended for forensic and research applications.

4-CN-BINACA-ADB is intended for research purposes only and is NOT intended for human or animal consumption.


4-CN-BINACA-ADB is a synthetic cannabinoid. It is a member of the indazole family of cannabinoids, specifically an indazole-3-carboxamide type. It is closely related to a series of such compounds developed by Pfizer in 2009. These were originally in development as painkillers. Like most indazole synthetic cannabinoids, this is a powerful CB1 agonist. There is little formal data available, but anecdotal evidence suggests an active dose as low as 1/10th of a milligram.

  • Project Type: Photography
  • Skills Needed: Photoshop
  • Customer: Example Inc
  • Project Year: 2013
  • Website: http://www.example.com